Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q15118
UPID:
PDK1_HUMAN
Alternative names:
Pyruvate dehydrogenase kinase isoform 1
Alternative UPACC:
Q15118; B2R6T1; B7Z937; D3DPD8; E9PD65; Q308M4
Background:
Pyruvate dehydrogenase kinase isoform 1, a mitochondrial enzyme, plays a pivotal role in metabolic regulation by phosphorylating PDHA1 and PDHA2. This action inhibits pyruvate dehydrogenase, controlling the flow through the tricarboxylic acid cycle, reducing aerobic respiration, and preventing acetyl-coenzyme A formation from pyruvate. It is crucial for cell proliferation under hypoxia and offers protection against apoptosis due to hypoxia and oxidative stress.
Therapeutic significance:
Understanding the role of Pyruvate dehydrogenase kinase isoform 1 could open doors to potential therapeutic strategies.